Federated Hermes Inc. Cuts Stake in ICU Medical, Inc. $ICUI

Federated Hermes Inc. cut its position in ICU Medical, Inc. (NASDAQ:ICUI) by 8.9% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 185,494 shares of the medical instruments supplier’s stock after selling 18,034 shares during the period. Federated Hermes Inc. owned approximately 0.75% of ICU Medical worth $24,513,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in ICUI. Gabelli Funds LLC raised its holdings in ICU Medical by 8.5% in the 2nd quarter. Gabelli Funds LLC now owns 76,500 shares of the medical instruments supplier’s stock worth $10,109,000 after acquiring an additional 6,000 shares during the last quarter. First Trust Advisors LP increased its holdings in shares of ICU Medical by 78.3% in the 2nd quarter. First Trust Advisors LP now owns 15,935 shares of the medical instruments supplier’s stock worth $2,106,000 after purchasing an additional 6,998 shares in the last quarter. Invesco Ltd. increased its holdings in shares of ICU Medical by 4.4% in the 2nd quarter. Invesco Ltd. now owns 212,718 shares of the medical instruments supplier’s stock worth $28,111,000 after purchasing an additional 8,891 shares in the last quarter. River Road Asset Management LLC raised its stake in shares of ICU Medical by 207.0% in the second quarter. River Road Asset Management LLC now owns 651,492 shares of the medical instruments supplier’s stock worth $83,658,000 after purchasing an additional 439,263 shares during the last quarter. Finally, Lido Advisors LLC purchased a new stake in shares of ICU Medical during the second quarter valued at $291,000. Hedge funds and other institutional investors own 96.10% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of ICU Medical in a research report on Wednesday, October 8th. Piper Sandler boosted their price objective on shares of ICU Medical from $153.00 to $172.00 and gave the company an “overweight” rating in a report on Friday, November 7th. Wall Street Zen downgraded shares of ICU Medical from a “buy” rating to a “hold” rating in a research report on Saturday, November 15th. Finally, KeyCorp lifted their target price on shares of ICU Medical from $173.00 to $175.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, ICU Medical has an average rating of “Moderate Buy” and a consensus target price of $181.75.

ICU Medical Stock Performance

Shares of ICUI opened at $142.48 on Wednesday. The business has a 50-day simple moving average of $130.43 and a two-hundred day simple moving average of $128.97. The company has a quick ratio of 1.19, a current ratio of 2.45 and a debt-to-equity ratio of 0.62. ICU Medical, Inc. has a 52 week low of $107.00 and a 52 week high of $175.51. The stock has a market cap of $3.52 billion, a price-to-earnings ratio of -459.60 and a beta of 0.82.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $2.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.43 by $0.60. The company had revenue of $533.30 million during the quarter, compared to the consensus estimate of $511.46 million. ICU Medical had a positive return on equity of 7.71% and a negative net margin of 0.32%.The firm’s revenue was down 8.9% on a year-over-year basis. During the same period in the previous year, the company posted $1.59 EPS. ICU Medical has set its FY 2025 guidance at 7.350-7.650 EPS. On average, analysts expect that ICU Medical, Inc. will post 4.11 EPS for the current year.

Insider Buying and Selling

In related news, VP Virginia Ruth Sanzone sold 930 shares of the company’s stock in a transaction on Tuesday, November 11th. The shares were sold at an average price of $142.34, for a total value of $132,376.20. Following the completion of the transaction, the vice president owned 5,456 shares of the company’s stock, valued at approximately $776,607.04. This represents a 14.56% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Elisha W. Finney sold 1,285 shares of the firm’s stock in a transaction dated Tuesday, November 11th. The shares were sold at an average price of $140.42, for a total value of $180,439.70. Following the sale, the director directly owned 3,995 shares in the company, valued at approximately $560,977.90. This represents a 24.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 1.50% of the company’s stock.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.